The activation and regulation of coagulation Factor XIII (FXIII) protein has been the subject of active research for the past three decades. Although discrete evidence exists on various aspects of FXIII activation and regulation a combinatorial structure/functional view in this regard is lacking. In this study, we present results of a structure/function study of the functional chain of events for FXIII. Our study shows how subtle chronological submolecular changes within calcium binding sites can bring about the detailed transformation of the zymogenic FXIII to its activated form especially in the context of FXIIIA and FXIIIB subunit interactions. We demonstrate what aspects of FXIII are important for the stabilization (first calcium binding site) of its zymogenic form and the possible modes of deactivation (thrombin mediated secondary cleavage) of the activated form. Our study for the first time provides a structural outlook of the FXIIIA2B2 heterotetramer assembly, its association and dissociation. The FXIIIB subunits regulatory role in the overall process has also been elaborated upon. In summary, this study provides detailed structural insight into the mechanisms of FXIII activation and regulation that can be used as a template for the development of future highly specific therapeutic inhibitors targeting FXIII in pathological conditions like thrombosis.
The fibrin stabilizing factor or coagulation factor XIII (FXIII) is a heterotetrameric protein complex, circulating in the plasma as a 320 KDa molecule consisting of a dimer of A subunits (FXIIIA2, 83 kDa) and a dimer of B subunits (FXIIIB2, 80 kDa)1,2,3. FXIII belongs to the transglutaminase family of enzymes (EC 188.8.131.52)4. The catalytic FXIIIA2 subunit possesses transglutaminase activity that covalently crosslinks fibrin polymers to confer resistance against premature fibrinolysis5. Deficiency of FXIII can result in a bleeding predisposition from acquired or inherited causes6,7. Patients with severe inherited FXIII deficiency (complete absence or loss of function) suffer from severe bleeding tendencies. Inherited severe FXIII deficiency is a rare autosomal disorder with a global average of approximately 1–4 out of a million individuals being affected6. However, a more frequently inherited form of FXIII deficiency is the heterozygous form that is usually associated with a mild or even asymptomatic phenotype6,7,8,9,10,11. This form is difficult to detect and, therefore is currently under-reported and poorly characterized. The past few decades of research have shown FXIII to have multiple pleiotropic functions12. It is known to play roles in maintaining vascular permeability, in development of extracellular matrix in bone and cartilage, in fostering cardioprotective effects, as a first line of defense against invading pathogens and, as recently reported, in pre-adipocyte differentiation and arthritis13,14,15,16,17,18. Identification and cloning of the F13A1 and F13B genes, along with the recombinant expression of the FXIIIA2 and B2 subunits19,20,21, was followed by high-resolution structural determination of the FXIIIA2 dimer in zymogenic forms22,23,24,25. Recently the structure of calcium-activated and inhibitor-stabilized FXIIIA subunit (FXIIIAa) was solved which shows remarkable differences from the zymogenic form26. Structurally, the FXIIIA subunit is composed of four sequentially arranged structural units: the beta sandwich, core, barrel-1 and barrel-2 domains. Unique to the FXIIIA subunit in the transglutaminase family is the presence of a 37 amino acid N-terminal activation peptide (FXIII-AP) which is cleaved by thrombin during FXIII activation. Despite early achievements investigating secondary structural elements and structural domains of FXIIIB21,26, progress in structure/function studies of this non-catalytic subunit have been slow and there are no high-resolution X-ray crystallographic or NMR structures for FXIIIB monomers, putative dimers, or for the FXIIIA2-bound conformation in FXIIIA2B2 tetramer. High primary sequence homologies with proteins from the complement system suggest that the monomeric FXIIIB subunit is composed of ten Sushi domains, each comprising ~60 amino acid residues21,27,28. Limited information exists on the interaction between FXIIIA and FXIIIB subunits and on FXIIIB2 dimerization29,30. The FXIIIB subunit is known to have a protective role, although more recently a regulatory role has also come to light31,32. The FXIIIA subunit has been a potential target for developing therapeutic inhibitors against thrombotic conditions. Earlier, the primary targeted region for developing therapeutic inhibitors was the thrombin cleavage site and the catalytic triad in the zymogenic form of the FXIIIA subunit33,34,35,36,37,38. With emerging details of structural changes taking place during FXIII activation, the activated form (FXIIIAa) is being considered as a good potential target26,38. The activation of the FXIIIA2B2 heterotetramer in plasma is an elaborate process involving the cleavage of FXIII-AP by thrombin combined with calcium binding which causes large-scale conformational changes in the FXIIIA subunit structure and also results in the dissociation of the FXIIIB subunits26,39. Although a number of studies by various groups have shed light on different aspects of this complicated process, however a comprehensive understanding of the complete activation process is lacking. In the current study we present a structure/function study of the chain of events comprising FXIII heterotetramer dissociation, FXIIIA subunit activation and subsequent down-regulation. We use computational analysis to elucidate structure/function associations that relate various stages of the entire FXIII pathway. Complimentary to this, we performed gel filtration analysis to characterize the dissociation of the FXIIIA2B2 heterotetrameric complex in different local biochemical conditions. In addition, we have tried to offer an alternative explanation for the regulatory role of FXIIIB subunit on FXIIIA activation in vitro. Finally, we compare observations and conclusions from the present study with results and conclusions derived from past literature.
Materials and Methods
Simulation and comparison of FXIIIA2 and Transglutaminase-2 structures
In order to understand the inter-residue relationships within the different parts of FXIIIA subunit and tissue transglutaminase-2 (TG2) plain molecular dynamics (MD) simulation was performed on the zymogenic human FXIIIA2 crystal structure (PDB ID: 1f13; 2.1 Å resolution)24 and the zymogenic TG2 structure (PDB ID: 1kv3; H. Sapiens species; 2.1 Å resolution)40 using the YASARA Structure package version 13.11.141,42. Gaps or unresolved regions within the crystal structure(s) were modeled them on the FREAD loop modeling server (http://opig.stats.ox.ac.uk/webapps/fread/php/; accessed on 05.10.2014)43. For e.g. the PDB file 1f13 that is unresolved at the thrombin cleavage site Arg37-Gly38 was submitted to the server under default parameters. The final structurally resolved structure was chosen based on scores that were a combination of all backbone atom anchor match RMSD(corresponds to the base structure) and all backbone atom loop match RMSD (corresponds to the loop structure). The PDB files were initially subjected to 500 ps of refinement MD simulation using YAMBER3 force field parameters in YASARA in order to remove steric clashes and improve rotamer geometry41. The file with the lowest energy in the simulation trajectory was chosen for conducting further simulations. In order to simulate the structures, a simulation cell with periodic boundaries and 20 Å minimum distances to protein atoms was employed with explicit solvent. The AMBER03 force field, NPT ensemble was used with long range PME potential and a cut-off of 7.86 Å44. Hydrogen bond networks were optimized using the method of Hooft and co-workers45. The simulation cell was filled with water at a density of 0.997 g/mL and a maximum sum of all bumps per water of 1.0 Å. The simulation cell net charge was neutralized with a final 0.9% (wt/vol) NaCl concentration. The entire system was energy minimized by steepest descent to remove conformation stress within the structure, followed by simulated annealing minimization until convergence was achieved. The MD simulation was performed at three different temperatures i.e. 298 K, 340 K and 370 K. Simulations for both structures were run for 100 ns (nanoseconds). Structural image visualization, analysis and rendering were done with YASARA 13.11.1 and Chimera version 1.10.242,46. Solvation energies for initial crystal structures as well as for simulation trajectory snapshots were calculated by submitting trajectory converted PDB-formatted files to the PDBePISA server (http://www.ebi.ac.uk/pdbe/pisa/pistart.html; accessed on 05.01.2015)47. Electrostatic surface potential was calculated and graphically depicted using the Adaptive Poisson-Boltzmann Solver integrated within YASARA48. The extent of correlated motion calculated in YASARA for all simulations is represented by C(i, j). It is collected in matrix form and displayed as a three-dimensional dynamic cross-correlation map (DCCM). The time scale is implicit in the C (i, j) values. The cross correlation was calculated as average over the time period of the entire trajectory. Positively correlated residues move in the same direction, whereas (negatively) anti-correlated residues move in the opposite direction. A completely correlated or anti-correlated motion, C (i, j) = 1 or C (i, j) = −1, means that the motions have the same phase and period. Blue color represent value 1 and yellow −1, all intermediate values are depicted by shades which are semi-proportionate mix of these two colors. The color code is represented as an inset diagram for all matrices.
Removal of bound calcium from zymogenic FXIII crystal structures using steered molecular dynamic simulation
Steered molecular dynamics (SMD) simulation was performed on the monomer (A chain) of the calcium-bound (at Ala457, Cab1) human FXIIIA subunit zymogenic structure (PDB ID: 1 ggu; 2.1 Å resolution)25 to simulate relocation of bound Ca2+ ions into the bulk solvent. The PDB file was passed through a refinement simulation protocol (described before) to generate an energy minimized structure before conducting the SMD41. The SMD simulation was conducted in two steps: 1) An initial 10 ns classical MD simulation with parameters as described above (for files 1f13 and 1kv3) followed by 2) a steered simulation during the production phase in which steering potentials were applied on the complex. After 10 ns of classical MD run, a steering force with an acceleration of 1000 pm/ps2 (picometre/picosecond square) was imposed on the bound ligand Calcium. The direction of the force was applied from the geometric center of the receptor to the geometric center of the ligand. The steered simulation was halted and analyzed at the point at which the Ca2+ ion was displaced into and completely surrounded by hydrated counter ions. No part of the whole system was restrained during the production phase SMD or the initial MD. Upon reaching the simulation end point, the resulting protein models and the simulation averaged structures were compared to the starting crystallographic structures and scored for backbone alpha-carbon (or side chain atom) Root mean squared displacement (RMSD). The simulation trajectory was also analyzed for variations in RMSD and Root mean square fluctuations (RMSF). A plain MD simulation with parameters similar to those described for 1f13 and 1kv3 in the earlier section was also run with two PDB files: 1) the simulation refined 1 ggu file with calcium bound at the first calcium binding site 2) a simulation refined 1 ggu file but with the calcium manually removed from its first calcium binding site. These simulations were run for 100 ns each at 298 K, 340 K and 370 K and the simulation end point structures and simulation averaged structures were compared with each other by structural alignment (results shown in main images correspond only to simulation run at 298 K).
Steered molecular dynamic simulation of zymogenic FXIII structures with and without the activation peptide
A similar SMD methodology to the one applied for calcium removal from zymogenic FXIIIA was employed for simulating dissociation of individual monomers from two separate homodimeric FXIIIA2 structures: one a zymogenic human Factor XIIIA2 structure including the activation peptide (PDB ID: 1f13; 2.1 Å resolution) and the other with N-terminal FXIII-AP residues through Pro39 deleted. Like before both structures were initially minimized using a structure refinement protocol41. A steering force with an acceleration of 100 pm/ps2 was then applied to displace monomer chain B from monomer chain A. No part of the whole system was restrained during the SMD or the initial MD to allow freedom of movement for residues being influenced by the separation of the monomers. The SMD was analyzed to the point at which no intermolecular contacts were observed between the FXIIIA monomers and/or the atoms started crossing the periodic boundaries.
Modeling all-atom factor XIII activation pathway intermediates
To generate FXIII activation pathway intermediate structural models, we used two crystal structures of FXIIIA2: the starting zymogenic FXIIIA2 crystal structure (PDB ID: 1f13; 2.1 Å resolution) and the non-proteolytically (high Ca2+ concentration) activated FXIIIAa crystal structure (PDB ID: 4kty; 1.8 Å resolution)24,26. The intermediates were generated by submitting these two structures as end-state structures to the ANMPathway server (http://anmpathway.lcrc.anl.gov/anmpathway.cgi; accessed on 08.11.2014), which uses a coarse-grained modeling approach to construct a two-state potential calculated by combining two elastic network models (ENMs) representative of the experimental structures representing the beginning and end points of the simulation49. Intermediate structures are extracted as snapshots along continuous steepest descent pathways generated for the protein atomic coordinates during the transition from beginning to end point structures. Since the server requires the beginning and end states to be similar in terms of molecular content, all atoms and molecules not common to both input structural coordinate files were deleted, missing/unresolved residues were modeled by modeling them (as described before) and only monomeric chains from each file were submitted. The AMNPathway server replaces amino acid side-chain atoms with a single representative vdW shell and returns alpha-carbon backbone traces without explicit side chain atoms as results. Once a large number of coarse grained intermediates were generated, eight were finally selected which differed from each other by at least >2 Å RMSD (of the alpha carbons of the backbone trace). The side chains of these intermediates were modeled using the PD2 ca2main server (http://www.sbg.bio.ic.ac.uk/~phyre2/PD2_ca2main; accessed on 25.11.2014) to generate the corresponding full atom models50. Full atom models were then subjected to a structure refinement protocol as described before41. Lowest energy models were selected from the simulation trajectory and analyzed. All the transition intermediate as well as end state models have been deposited in the protein modeling database (https://bioinformatics.cineca.it/PMDB/main.php) (PMDBID: PM0080129-PM0080136).
An all-atoms partial heterotetrameric model of FXIIIA2B2
In order to generate a partial model of the FXIIIA2B2 heterotetramer, we used a step-wise approach to first generate a dimeric modeled structure of FXIIIB2, followed by a constrained docking of a limited number of contiguous Sushi domains on the zymogenic FXIIIA2 subunit crystal structure. A threaded model of a monomeric FXIIIB subunit was at first generated on the I-TASSER server (http://zhanglab.ccmb.med.umich.edu/I-TASSER/; accessed on 11.12.2014) with distance constraints applied for the known disulfide bonded cysteine’s within each Sushi domain of the FXIIIB subunit51. Since the auto generated structure had certain flaws i.e. absence of specific disulfide bond, presence of disordered structures in ordered (predicted) areas etc., all ten individual sushi domains of this threaded model were replaced with previously modeled structures of these domains while keeping the linker regions of the threaded monomeric FXIIIB subunit model28. The linker region of the automated structure was not touched in order to retain the backbone properties of this earlier model. The modified monomeric FXIIIB model was subjected to a round of model refinement simulation protocol as described before and the final energetic minimum monomeric structure was chosen from the trajectory41. The modified monomeric FXIIIB model was symmetrically dimerized using the M-ZDOCK docking server (http://zlab.umassmed.edu/m-zdock/; accessed on 12.01.2015), to generate a dimeric structure52. The ZDOCK server searches the translational and rotational space between the two proteins for all possible binding modes and evaluates and ranks each pose using an energy-based scoring function. The M-ZDOCK is an adapted from the ZDOCKing algorithm to predict structures of symmetric or cyclically symmetric multimers. The server generated (based on its scores) top ten docking poses, only one of which showed a head to tail (antiparallel) orientation with close proximity between the Sushi domains 4 and 9 on adjacent chains (with oppositely charged electrostatic patches) and this was chosen as the final model for the FXIIIB2 structure (based on current experimental data; see Supplementary methods for more details)29,53. The docking pose was energy minimized with a 100 ns long classical MD simulation with parameters as described before i.e. simulation of PDB files 1f13 and 1kv3 (trajectory details i.e. RMSD/energy values can be made available on request). The lowest energy conformers from these simulations were subjected to a model refining simulation protocol as described earlier41. The lowest energy structure from this simulation trajectory was chosen as the final FXIIIB2 subunit dimeric model. In the absence of adequate experimental data to enable co-operative docking of the FXIIIIB2 subunit Sushi domains on the FXIIIA2 subunit, we performed blind docking of only a symmetrically identical end component of the FXIIIB2 dimer model (consisting of Sushi domains 1, 2, 3 and 4 of one monomer and Sushi domains 8, 9 and 10 of the opposite monomer) onto a monomeric chain of FXIIIA2 zymogenic crystal structure using the Z-dock server (http://zdock.umassmed.edu/; accessed on 21.01.2015). The model with closest proximity between Sushi domains 1 and 2 (as per what is currently known for FXIIIA: FXIIIB subunit interactions) and the monomeric FXIIIA was chosen as the final model. This model was subjected to rounds of energy minimizing classical MD simulation followed by refining simulation protocol as applied for the B2 subunit. The lowest energy structure from the final refinement protocol was once again chosen as the final model. The docked FXIIIA-FXIIIB (S1–S4 antiparallel S8–S10) model was then converted into a partial heterotetramer by dimerizing it using the M-ZDOCK server as described above. In this specific docking, all known non-interface residues (identified from the PDB file: 1f13 using PDBePISA) of the FXIIIA2 dimer were used as a negative constraint. This gave us a final partial heterotetrameric model of FXIIIA2B2 (S1–S4 antiparallel S8–S10). This final model was not subjected to any more rounds of classical MD simulation but minimized directly by refining it with the previously described 500 ps refinement protocol. However, in order to test for the stability of this docked complex it was subjected to 100 ns of classical MD simulation post the refinement simulation, following parameters described for the simulation of PDB files 1f13 and 1kv3. The primary FXIIIA2B2 heterotetrameric partial model has been deposited in the protein modeling database (https://bioinformatics.cineca.it/PMDB/main.php) (PMDBID: PM0080128).
Dissociation of FXIIIB (S1–S4 antiparallel S8–S10) subunit component from the partial FXIIIAB heterodimer by steered molecular dynamic simulation
A similar methodology to the one applied for dissociating bound calcium from the zymogenic FXIIIA molecule was employed for dissociating the FXIIIB partial subunit component from the previously modeled partial FXIIIAB heterodimer [i.e., consisting of one half of the previously generated partial heterotetrameric FXIIIA2B2 (S1–S4 antiparallel S8–S10) model]. A steering force with an acceleration of 200 pm/ps2 was applied on the FXIIIB subunit component. No part of the whole system was restrained during the SMD or the initial MD to allow freedom of movement for residues being influenced by the separation of the individual subunits. The steered simulation was analyzed to the point at which no intermolecular contacts were observed between the individual subunits and/or the atoms started crossing the periodic boundaries.
Gel filtration analysis of the activation of FXIII A2B2 heterotetramer
Plasma concentrate Fibrogammin P (CSL Behring), was used a source of human Factor XIII heterotetramer. FXIII was purified using gel filtration chromatography on a Superdex 200 10/300 GL column (GE Healthcare). Briefly, the column was equilibrated with running buffer (30 mM Tris, 150 mM NaCl, pH 7.4), Fibrogammin P was loaded and fractions were eluted. Fractions corresponding to the molecular weight of FXIII heterotetramer (~320 kDa), were collected and sequentially re-purified thrice until a single, homogenous, monodispersed peak was observed. For each set of in vitro activation experiments, 25 μg of purified FXIIIA2B2 dissolved in 20 mM Tris, 120 mM NaCl, pH 7.4 buffer was incubated with 46.2 U/mL of thrombin (Sigma, USA), at different concentrations of calcium chloride (0 mM, 1 mM, 2 mM, 5 mM, 10 mM and 25 mM), for 60 minutes at 30 degrees. Reaction product was filtered and resolved using a Superdex 200 PC 3.2/30 (GE Healthcare) analytical column. Peaks from samples loaded at different calcium ion concentrations were collected and analyzed on Native PAGE (Life technologies, Germany). The observed bands were analyzed and confirmed for the presence of FXIIIA and FXIIIB by Mass Spectrometry (see Supplementary Data).
Spiking FXIIIB during activated FXIIIA (FXIIIAa) generation
FXIIIAa generation was triggered by tissue factor/phospholipids (TF/PL) and FXIIIa isopeptidase activity was measured using the fluorogenic substrate A101 (Zedira, Darmstadt, Germany) in a Safire microtiter plate reader (Tecan, Craislheim, Germany)54. Twenty five microliters human standard plasma (Siemens Healthcare, Marburg, Germany) or FXIII-deficient plasma (deficient for FXIIIA2 and FXIIIB2; Haemochrom Diagnostica GmbH, Essen, Germany) spiked with rFXIII-A2 (1 IU/mL) or a mixture FXIIIA2 (1 IU/mL) (Purified in-house, see Supplementary data) and rFXIIIB2 (10 μg/mL) (Zedira, Darmstadt, Germany) were incubated with 35 μL reagent solution (5 μL 100 mM glycine methyl ester, 5 μL 2 mM fluorogenic FXIIIa substrate, 10 μL Innovin (recombinant TF; Dade Behring, Liederbach, Germany) diluted 1:2800 in phospholipids (PTT reagent kit, Roche, Mannheim, Germany) and 15 μL HBS (20 mM Hepes, 150 mM NaCl)/0.1% serum albumin pH 7.5. After pre-incubation of the mixture for 5 minutes, the reaction was started with 40 μL 25 mM CaCl2 pH 7.5. Fluorescence was measured over 1 h at λex = 330 nm and λem = 430 nm in kinetic mode 2 times per minute. The curve data was evaluated according to a bi-exponential model with first order absorption and elimination. Data were fitted to the equation:
where ka – constant of absorption which describes the development of FXIIIa and kb – elimination constant. The parameters area under the curve (AUC), peak FXIIIa concentration (CP) and time to peak (TTP) were also evaluated.
Simulation and comparison of FXIIIA2 and TG2 models: Structure/sequence differences between FXIIIA2 and TG2 account for their respective functional evolution
The FXIIIA (monomeric chain A) and TG2 zymogenic structures show perfect alignment of the respective domains except for the absence of the FXIII-AP region in TG2 (Figure S1). TG2 is known to bind 6 calcium ions of which 5 non-canonical sites have been characterized by mutagenesis13. The monomeric chain of the FXIIIA subunit possesses only 3 calcium binding sites (Cab1–3), but with similar spatial correlation to homologous TG2 sites. The RMSD graphs during the simulation run for both these structures at different temperatures are shown in Figure S1. The simulation for both FXIIIA2 and TG2 PDB files stabilized around ~2–2.5 Å RMSD after 10 and 40 ns respectively (total energy of the systems ~−37 × 106 kJ/mol and −29 × 106 kJ/mol respectively). For the FXIIIA2 and TG2 structures we observed a positive correlation (DCCM) between the residues of the separate calcium binding sites (TG2 mean C (i, j) = 0.462; FXIIIA2 mean C (i, j) = 0.186) (Figure S3). The TG2 redox switch14, which consists of two vicinal disulfide bonded cysteine’s, lies in a highly conserved region of FXIIIA2, although one of the cysteine’s is substituted by an arginine in FXIIIA2 which precludes the possibility of formation of an allosteric disulfide bond in FXIIIA2. The GTP/GDP binding site15 (Arg478/Ser482) of TG2 is not conserved in the FXIIIA2 dimer (Figure S1). Instead, the region aligns with a sequence of the FXIIIA subunit that forms a secondary thrombin cleavage site (Figure S2, Lys513/Ser514)5.
A constitutively bound calcium at Cab1 stabilizes the zymogenic form of FXIIIA2
Applying simulated dissociative force (using SMD) on calcium to remove it from the constitutively bound site at Cab1 of FXIIIA results in significant change of structure (>2 Å RMSD) around the FXIII-AP cleavage site (Fig. 1). Prior to MD simulation to displace bound calcium, this region was part of an ordered beta sheet (the regions between residue numbers 27–31 and 168–172 constitute two antiparallel beta strands stabilized by means of 4 hydrogen bonds). During simulation, these 4 hydrogen bonds that stabilize the sheet were lost and the antiparallel beta strands assumed a disordered random coils conformation for most of the simulation time. Interestingly, this region is spatially distant (>10 Å) from the calcium binding site, therefore the observed modeled structural change is most likely consistent with an allosterically mediated calcium binding effect. The plain MD simulation of calcium bound 1 ggu file did not show any remarkable differences in secondary structure post 100 ns of simulation in this region around the thrombin cleavage site [the Fig. 1 Panel A clearly shows that even post 100 ns of simulation this region is represented by a beta sheet (green colored)]. However when we simulated the 1 ggu PDB file after manually removing the bound calcium for 100 ns, we observed the loss of ordered secondary structure (see Fig. 1 Panel A; the red and blue backbone structures corresponding to this region in the shaded areas are disordered) in the region around the cleavage site as observed during the SMD in which calcium was pulled out. Unusually high RMSF values were observed in simulation averaged structures of the plain MD run for 1 ggu without calcium as well as for the SMD, but none for the plain MD run for 1 ggu with bound calcium (Fig. 1 Panel D; spikes 1 and 2; results correspond to simulations done at 298 K only although similar observations were registered for 340 and 370 K as well). The RMSD graphs for plain simulations run on the PDB files of 1 ggu with and without calcium are depicted in Figures S4. These figures show that both structures are relatively stable with or without calcium, although the PDB file without calcium achieves its RMSD plateau ~0.2 Å higher than with calcium which might be attributed to RMSD changes occurring around the thrombin cleavage site. Structural alignment of the simulation averaged structures from both simulations shows little overall structural difference (average RMSD: 1.342 Å). However a significantly higher average RMSD of 5.6 Å was observed between the thrombin cleavage site and neighboring residues (considering the P1–P4 and P1′–P4′ residues) of the two simulation averaged structures. This indicates local changes in structure (and hence of accessibility) around the thrombin cleavage site sessile bond following the removal of calcium.
The activation peptide is the major contributor to the dimeric interface of the zymogenic Factor XIIIA2 and its cleavage weakens the dimer interaction
The SMD simulation to dissociate the individual monomers of FXIIIA2, with and without the FXIII-AP sequence, revealed that the structure without FXIII-AP becomes dissociated in less time (30 ns) at a constant separation force than the dimer with the intact activation peptides (60 ns) (Fig. 2, Panel A). The absence of FXIII-AP also results in a weaker interaction between non-FXIII-AP residues within the dimeric interface. The mean solvation energies of the residues on these interfaces (estimated from the simulations) are lower, exemplified by greater negative calculated values for the structure without FXIII-AP (Fig. 2, Panel B). Also, the residues that become separated by the end of the simulation are responsible for FXIII-AP/core domain interactions as judged by comparison with the starting crystallographic structure. The activation peptide residues show positive correlation [mean C (i, j) = 0.762] with respect to the rest of the dimeric interface residues (during the SMD of the zymogenic FXIIIA with FXIII-AP) (Fig. 2, Panel C). We observe that the interaction of two neighboring Arg residues on FXIII-AP, Arg11 and Arg12 with Asp343 and Glu401, respectively, on the core domain of the apposing monomer may be critical to the dimeric stability of the FXIIIA subunit structure since as observed, these interactions were last to be separated during simulation of subunit dissociation. The mean correlation value for these four residues with the rest of the dimeric interface is negative [mean C (i, j) = −0.647] indicating that they are displaced from their starting positions in a manner consistent with opposition to the dissociative forces experienced during the overall simulation.
MD simulation suggests large conformational changes upon activation of FXIIIA is affected by calcium binding at three sites in a temporal manner
The end state models of the activation path intermediates show overall similarity in secondary structure although the complete backbone moves to a large extent (Figure S5). Comparison of models in the series suggests major changes in secondary structure in the region between residues 450 and 650 (intermediates 2 through 5) which is affected by local changes in calcium binding at Cab1 and Cab2 (Fig. 3). Changes in backbone structure during the simulation are initially observed around the beta sandwich region and parts of core and barrel-1 domains (Fig. 3, RMSD graphs). Structural changes shift to core domain, barrel-1 and barrel-2 in successive intermediates and translate to and/or rotate the two barrel domains with respect to each other and with respect to the core domain. Finally, backbone conformational changes appear to alternate between the barrel-1 and barrel-2 domains during the course of the transition, which results in movement of the barrel domains across their common plane of symmetry, thereby twisting the final molecule three dimensionally while causing the FXIIIA subunit to unfold like a jackknife (Fig. 3). During the simulation, the first calcium binding site (Cab1) becomes disrupted as the second calcium binding site (Cab2) is unmasked and coordinates a Ca2+ ion. The distance between Glu401 and His342 residues (referred as catalytic diad), which are distant in the zymogenic form, decreases through the early intermediates 1–4 (Fig. 4, Panel A, sections i, ii). This simulated movement appears to be a consequence of intermittent switching between beta strand and coil forms for the backbones of both Glu401 and His342 those results in a flapping movement of these residues close and then subsequently away from each other. A hydrophobic pocket, whose base is occupied by the catalytic Cys314 residue, emerges along with a hydrophobic tunnel formed by the movement of the planar rings Trp370 and Trp279 (also as a result of Cab2 coordination), which are finally stabilized by aromatic stacking interactions (Fig. 4, Panels A, B). On one side of this tunnel is the K substrate (Lysine substrate) entrance site and the other side is the His342/Glu401 diad known to guide the Q substrate (Glutamine substrate) to the base of the hydrophobic pocket where a positively charged oxyanion hole, formed by electronegative backbone carbonyl groups of both Cys314 and Trp279, is located. This oxyanion hole stabilizes the substrate-enzyme intermediate (Fig. 4, Panel B).
The all-atoms partial heterotetrameric model of FXIIIA2B (S1–S4 S8–S10)2 suggests that bound FXIIIB subunits mediate regulation of FXIII activation
A flowchart for the generation of the FXIIIA2B partial heterotetrameric model is presented in Figure S6. The FXIIIB2 subunit dimeric model is symmetric, long and filamentous as has been suggested from electron microscopy based studies (approximately 21.5 nm end to end)27. The first two N terminal Glu residues for this model were skipped from the final structure owing to conformational equilibrium purposes. This model had regions around sushi domains 4 and 9 interacting with each other on the opposite chains in a head to toe manner and therefore the overall structure was symmetrical. The regions around sushi domains 4 and 9 were observed to have oppositely charged surface electrostatic potential (Figure S7) which adequately fitted into each other. The final all-atoms partial heterotetrameric model was a symmetric fitting of the B subunit fragments around the A subunit. While the A subunit retained its former non-associated structure, the B subunit (fragments) appears to undergoe significant rearrangement to wrap around one side of the A subunit. This partial model for the FXIIIA2B2 complex was quite stable as can be seen from the plain simulation runs performed at 298 K in which it hits a equilibrated RMSD plateau around the 2.5 Å mark (c-α backbone RMSD)(Figure S8). Plain simulations performed at 370 K showed significantly higher RMSDs approaching the 3.5 and 4.5 Å respectively mark at 100 ns of runtime which is not unusual for a non covalently associated complex plus this model is lacking in possible binding contributory domains. The all-atoms partial heterotetrameric model of FXIIIA2B2 (Fig. 5, Panel A) suggests an interaction between the variable length loop region of FXIIIB Sushi domain 1 (Residues Tyr18-Pro28) with the N-terminal residues (Thr6-Asp25) of the FXIIIA subunit activation peptide (Fig. 5, Panel C). The interaction appears to be primarily hydrophobic since although the activation peptide region bears a strong positive electrostatic potential, the variable length loop of Sushi domain 1 is electrostatically neutral. Other regions of interaction are defined in Fig. 5, Panel B. In this model, the Cab1 site is always exposed and therefore occupied by a calcium ion, Cab2 is occluded by the FXIIIB S1/FXIII-AP interaction surface, while the third Cab3 is partially occluded by the FXIIIA2 dimeric interface, but, more significantly, by the FXIIIB2 subunit Sushi 1/Sushi 2 domains from apposing monomers.
Intermediate partial FXIIIA2B (S1–S4 S8–S10)2 complex models generated during SMD simulated activation suggest successive weakening of intersubunit interactions
Simulated dissociation of the modeled partial monomeric component of the FXIIIB subunit from the monomeric FXIIIA structure using our SMD method resulted in a sharp change in estimated solvation energy for residues which spatially surround the three calcium binding sites (Fig. 6, Panel C). From a calculated dynamic cross correlation matrix (DCCM) for the simulation we infer that the three calcium binding site residues show a negative correlation with beta sandwich domain residues of FXIIIA subunit interacting with the FXIIIB subunit (Fig. 6; Panel A). In contrast, the residues from the other C-terminal domains (Barrel domains) of the FXIIIA subunit that interact with the FXIIIB subunit show a strong positive correlation. This indicates that the motions influenced by calcium binding at the N- and C-terminals are opposite to each other, suggesting that the entire FXIIIA molecule will tend to twist. This twisting movement of the FXIIIA subunit suggests a mode for weakening FXIIIA: FXIIIB subunit interactions within the heterotetramer. The last FXIIIA subunit residues to lose contacts with the FXIIIB subunit during this simulation are Asn175, Asp297 and Lys677 (Fig. 6, Panel B). Interestingly, simulated dissociation of the FXIIIB subunit from the FXIIIA subunit also distorts the region around the FXIII-AP cleavage site lowering the accessibility around the Arg37-Gly38 sessile bond (Fig. 5, Panel D).
Presence of the FXIIIB subunits accelerates the rate of in vitro activation of FXIIIA2
Results of the in vitro FXIIIA activation assay (see Supplementary Methods)52 revealed that, in the absence of FXIIIB, the rate of generation of FXIIIAa is lower (ka = 0.145, where ka is constant which describes the absorption of FXIIIa development in a one compartment model) than when FXIIIB is present (ka = 0.485). The lag time in FXIIIAa generation assay was shortened by 9.45 minutes when rFXIIIB (Zedira, Darmstadt, Germany) was added to rFXIIIA in FXIII-deficient plasma (Figure S9). The time course for FXIIIAa generation for rFXIIIA in the presence of added rFXIIIB subunit resembled that of normal pooled plasma.
The FXIIIB subunits separate from the FXIII heterotetramer at high calcium ion concentration in the in vitro activation assay
Gel filtration analysis (Fig. 7) revealed that only at very high calcium ion concentration (25 mM) during activation, measured in vitro concentrations of FXIIIB subunit suggest that it completely dissociates from the initial FXIIIA2B2 complex (peak separation starts at in vitro calcium ion concentration: 5 mM/activation reaction mixture of 50 μl). The first eluted peak corresponded to the tetrameric FXIIIA2B2 complex as determined by mass spectrometry, while the second peak contained only FXIIIB2 (Figure S10). No dissociated FXIIIA2 or activated FXIIIAa was observed in any of the eluated peaks. The second peak corresponding to FXIIIB appeared distinctively when the concentration of calcium ions exceeded 5 mM in the reaction mix applied to the column. In the absence of thrombin cleavage, however, no separation of subunits was observed irrespective of calcium ion concentration (0–25 mM). The resolved FXIIIA2B2 and FXIIIB2 peaks at different calcium concentrations exhibited different elution times (Fig. 7).
The activation of FXIII in vivo follows a sequence of events that is initiated by proteolytic cleavage, calcium binding and ensuing conformational changes. In the present report we attempt to rationalize the complete train of molecular events with an eye on plausible sub-molecular conformational changes that may take place during this process. The structural and sequence alignment of FXIIIA subunit to the better characterized homologous TG2 transglutaminase suggests a few insightful observations. Firstly, both enzymes share identical domain organization except for an additional activation peptide (FXIII-AP) absent in TG2 and which is cleaved by thrombin in the first step of in vivo FXIII activation. In vivo, TG2 remains inactive until binding of GTP/GDP at low intracellular calcium levels55. At relatively higher extracellular calcium concentration and low concentration of GTP/GDP, a redox switch involving two vicinal cysteine’s (Cys408-Cys409) regulates TG2 activation56. The homologous region of FXIIIA, where the vicinal cysteine’s are substituted by Arg408-Cys409 of FXIIIA, forms the central core of the dimeric interface of FXIIIA2 and is also part of the buried Cab3 site in the zymogenic FXIIIA subunit structure. Therefore, this homologous region of FXIIIA appears to have evolved as part of a regulatory mechanism (instead of a redox switch) that stabilizes the dimeric interface, occluding the solvent access to the Cab3 binding site. Residues involved in GTP/GDP binding of TG2 (Arg478/Ser482) align with a secondary thrombin cleavage site (Lys513/Ser514) of FXIIIA which suggests that this region interacts with the FXIIIB subunit, instead of GTP/GDP, to prevent secondary cleavage of zymogenic FXIIIA (Figure S1). Therefore, these two homologous regions apparently have regulatory functions in protecting/maintaining the zymogenic form of either protein, although the biochemical nature of the binding partner is different for the two transglutaminases.
Our results suggest that the calcium binding sites of TG2 and FXIIIA serve to coordinate and stabilize conformational changes during a multistep activation process that directs a global change in the respective protein folds and leads to exposure of enzymatically competent active sites. We observed a mean positive dynamic correlation between the movement of different calcium binding site residues with respect to each other when simulating activation of the zymogenic TG2 and the FXIIIA structures. This suggests mutual interdependence and possibly cooperativity between these calcium binding sites during the activation of both structures (Figure S2). Interestingly though, unlike TG2 in which all individual cross-correlations between individual calcium binding sites were positive, in FXIIIA the individual cross-correlation of Cab1 with Cab2 and Cab3 [C (i, j) = −0.127 and −0.199] each were negative values which was compensated by a high positive correlation [C (i, j) = 0.886] between Cab2 and Cab3 value resulting in a positive mean correlation value [C (i, j) = 0.186] (Figure S2). Therefore unlike TG2, the saturation of calcium binding sites for FXIIIA may be a sequentially ordered set of events which is also consistent with conclusions drawn from our transition state intermediate model analysis (Fig. 5). In fact, the constitutively calcium-occupied Cab1 site of FXIIIA may impart a stabilizing influence on the zymogen structure, similar to the effect of GTP/GDP binding on TG2 intracellularly55. We observed that when we simulated dissociation of this calcium, there appeared to be an allosteric effect on the region around the FXIII-AP that suggests it may change conformation to a random coil from an ordered beta sheet. The same distortion was also observed in a plain simulation of the FXIIIA subunit 1 ggu file deprived of its bound calcium. On the other hand a plain simulation of the original calcium bound structure did not show the breakdown of the ordered secondary structure clearly indicating that the reason for the loss of order in the region around the activation peptide (even when the rest of the structure does not change much) is the absence of calcium at Cab1. Such a loss of secondary structure would tend to render it more susceptible to proteolytic attack (Fig. 1). This data explains an earlier observation in the literature, which reports that mutating the Cab1 binding site residues results in faster proteolysis of the zymogenic FXIIIA57.
Post thrombin cleavage, the Cab1-mediated zymogenic constraint is apparently lost when the Cab2 binding site becomes exposed and coordinates a calcium ion. The first four of a simulated temporal series of eight transition state intermediate models suggest that the co-ordination of the first two calcium binding sites may be antagonistic to each other (i.e., the bound calcium occupancy at Cab2 transiently destabilizes the Cab1 site) (Fig. 3). The cleavage of FXIII-AP may serve multiple roles. Firstly, it may expose Cab2 as discussed above. Secondly, SMD simulated dissociation of the subunits of the zymogenic FXIIIA2 dimer (with or without N-terminal FXIII-AP sequence) suggested that the absence of FXIII-AP results in a weakened dimeric interface (Fig. 2). A similar, supportive experimental observation was recently reported by Schroeder et al.32 using mutated FXIII-AP variants58. Lastly, the removal of FXIII-AP, according to our simulation analysis, may result in overall tendency towards heterotetramer dissociation, as supported by analysis of our partial heterotetramer model (Fig. 5). Our simulation analysis also suggests that the ionic co-ordination of Cab2 and Cab3 imparts a conformational change through forces on the peptide backbone that propagates N- to C-terminal, finally enabling the barrel-1 and barrel-2 domains to rotate/translate and convert the apoenzyme to the active form. The calcium coordination of the Cab2 site also confromationally alters residue conformations at the Cab3 site. Stieler et al. (2013) hypothesized that this rearrangement of the loop is critical for access of the K substrate (Lysine substrate) that enters the catalytic hydrophobic pocket from this direction26. We observed in our partial heterotetramer model that this region is masked partly by portions of the FXIIIB subunit. The rearrangements in the Cab3 site would potentially also weaken the FXIIIA: FXIIIB interactions, thereby increasing access of calcium in the aqueous mileu to the Cab3 site. With our transition state intermediate models we were able to reproduce and observe the calcium binding changes postulated by Stieler et al. (2013), but in an all-atoms dynamic representation across a short temporal window26. Furthermore, we were able to observe the formation of a hydrophobic catalytic pocket in which the acylenzyme Q substrate (Glutamine substrate) intermediate could be formed. The formation of a hydrophobic tunnel and the oxyanion hole that retains and stabilizes this intermediate was also observed in later stage transition intermediates (Fig. 4B). Such oxyanion holes have been reported not only for FXIII, but also in other transglutaminases as well as cysteine proteases that comprise a family of enzymes from which transglutaminases are thought to have evolved59. Movement of the His342-Glu401 diad residues towards each other in the early stage simulation intermediates and then away from each other in the final stages, was also observed in this study (Fig. 4A). Maurer et al. (2004 and 2007) observed that FXIIIA residues 513–522 showed decreased surface accessibility post-activation for both proteolytic and non-proteolytic activation pathways60,61. Among our simulated transition state intermediates, we observed that residue patch 501–522 in the zymogenic FXIIIA forms a V with an angle of 122° that closes upon itself in subsequent activation intermediates, thereby occluding access to residues 513–522. This would explain the decreased surface accessibility. Similarly, Maurer et al. (2004 and 2007) also showed that residues 523–546 also exhibited decreased accessibility only during non-proteolytic activation60,61. We believe that during non-proteolytic activation, the presence of FXIII-AP serves to retain the activated form of FXIIIA as a weak dimer, unlike in proteolytic activation where it apparently dissociates into monomers. We observed that, on application of simulated forces to separate the FXIIIA subunits, the dimer remains associated only through a few residues (Arg11, Arg12, Asp343 and Glu410) that form interactions between the FXIII-AP and the core domain. Our dissociation simulation results suggest that these associations will have the effect of rotating each monomer relative to the other during activation. As a result, residues 526–546 of one monomer would end up opposed to the analogous residues on the opposite monomer, effectively forming a rearranged interface for the weakened dimer and concomitantly preventing local solvent accessibility (Figure S11). This is also consistent with non-proteolytic activation of FXIIIA being reversible62.
When we simulated dissociation of the FXIIIB subunit from the FXIIIA subunit in the partially modeled heterodimer, we observed that structural rearrangements in the interface regions between FXIIIA and FXIIIB showed a strong correlation with rearrangements in the three calcium binding sites along with large variations in estimated solvation energies (Fig. 6). These two relationships in distant structural rearrangements suggest the interdependence of the rearrangements (i.e., the binding of calcium at Cab2 also contributes to weakening of the FXIIIA: FXIIIB interface and also causes local rearrangements at the Cab3 site). The final residues to dissociate in the FXIIIA dimer are from the core domain (Asn 175, Asp297) and barrel-2 domain, (Lys677) indicating that dissociation of at least a portion of the FXIIIB subunit is crucial to full exposure of the catalytic site as well as to the final movements of the barrel domains.
Our simulation suggests that saturation of calcium binding at Cab3 is likely the last molecular event leading to dissociation at the FXIIIA: FXIIIB interface. This is in agreement with our in vitro dissociation results observed by gel filtration when higher calcium concentrations resulted in increased dissociation of FXIIIB2 dimer from the primary heterotetramer FXIIIA2B2 (Fig. 7). The absence of FXIIIAa, as a resolved peak in our gel filtration results could be the result of subsequent inactivation or instability of FXIIIAa. This instability of FXIIIAa may be due to dissociation of FXIIIB subunits that would expose the secondary thrombin cleavage site of FXIIIAa 515–51663. Interestingly, when we analyzed the exposed surface area of activated FXIIIAa compared to that of the zymogenic form in our simulations, we identified a number of putative sites within additional surface exposed locations that would theoretically be susceptible to protease activity (Figure S12). The FXIIIA zymogenic form, as well as the activated form, has been shown in the literature to be susceptible to cleavage by proteases other than thrombin2,64. Also, cleavage by polymorphonuclear granulocyte proteases (PMN) has been suggested to be one of a number of possible down-regulation mechanisms for inactivating FXIIIAa within the fibrin clot65. We expect that activated FXIIIAa in the absence of bound FXIIIB is down-regulated in vivo primarily by sequential proteolytic degradation that might be initiated by thrombin. This also explains reports of its short circulating activity half-life in literature and in results of this study as well66. This aspect of down-regulation of FXIIIA requires further investigation, however, as we could not identify evidence of proteolyzed FXIIIA following the two major protein elution peaks observed in the present gel filtration experiments. Interestingly a very recent article suggests that Thrombin cleavage could be a means of FXIIIAa downregulation but only after primary cleavage by Plasmin67. The fact that our simulation results suggested that the FXIIIB subunit dissociates from FXIIIA only after the calcium binding site Cab3 becomes saturated is experimentally supported by the results of our gel filtration experiments. Specifically, the amount of FXIII heterotetramer resolved significantly decreased with increasing calcium concentration, but also appeared at different retention times which suggest that the complex structure undergoes some conformational transformation as a loose/weakened heterotetramer without the dissociation of FXIIIB subunit.
A secondary observation in this study, which has also recently been reported by two other groups35,36, was the influence of FXIIIB subunit on the activation of FXIIIA. We observed in FXIII generation assays (which mimic the physiological conditions) that addition of rFXIIIB2 to rFXIIIA2 accelerates activation (Figure S5). Ichinose et al.31 explained their similar observation by the interaction of FXIIIB2 subunit with fibrinogen35. However, in the same article they also elaborate that differences in the FXIIIB2 C-terminus (interaction site for Fibrinogen) as observed between FXIIIB subunit isoforms FXIIIB*1 and FXIIIB*3 do not affect fibrinogen binding and that there might be other contributing factors to this observation. We suggest an explanation for this observation using simulation result based on our partial heterodimeric model of FXIIIA2B. Specifically, our results suggest that Sushi domain 1 may dock onto a hydrophobic fold formed by the N-terminal part of the activation peptide (Fig. 5). Also, our simulation results suggest that dissociation of FXIIIB may cause the FXIII-AP sessile bond to be less accessible. We suggest that the putative hydrophobic interactions between the FXIIIB Sushi S1 domain and the FXIII-AP may allow increased efficiency in proximal thrombin cleavage. This is evident also from our FXIIIB subunit spiked FXIII generation assay, results where in the presence of FXIIIB accelerates the activation of FXIIIA. This combined with the data from activation peptide, suggests that the interactions of activation peptide with the opposite monomer of FXIIIA and the FXIIIB subunit maintain the region around the activation peptide in a spatial location ideal for insertion and cleavage by thrombin at the right time and place i.e. they both contribute to a perfect cleavage (neither too early nor delayed).
The entire simulated sequence of activation events described in our article would be expected to take place in the plasma (Concentration of calcium: Free ions 1.18 mmol/L, protein bound 1.14 mmol/liter, total 2.48 mmol/liter)68. The question then arises: What is the sequence of events involving activation for intracellular FXIIIA2? We assume that the dimeric FXIIIA2 molecule exists intracellularly as an ion regulated equilibrium between its activated and zymogenic state. Since the intracellular levels of calcium are lower than in plasma, the occluding effects of FXIII-AP and FXIIIB binding on the Cab2 and Cab3 calcium binding sites would not be expected to be consequential in vivo in cells. At low levels of calcium, only the Cab1 site would be occupied and, hence, a dynamic equilibrium shift towards the zymogenic state is expected. A change in this equilibrium might be caused by intracellular calcium influx under conditions when activation of intracellular FXIIIA2 is required. Therefore, saturation of Cab2 and Cab3 with calcium could occur without FXIII-AP cleavage, resulting in a reversible form of activation of FXIIIA2 possibly in a manner similar to our simulated results. Interestingly, it has been reported that FXIIIA2 can also be activated without thrombin cleavage and at low calcium concentration, but only on a very long time scale69. Thus, our results further suggest that all three calcium binding sites are occupied during the activation of FXIIIA irrespective of the type of activation.
To briefly summarize our work, this study provides some major insights into the activation and regulation mechanism of FXIII. In a stepwise manner we have shown how calcium binding regulates both the zymogenic and activated forms of FXIIIA. The information contained in the subtle structural changes observed in the various intermediates models can be used to design high efficiency inhibitors against FXIII. Additionally, for the first time our study lends a hypothetical structure functional perspective/account of FXIIIA: FXIIIB interactions during the dissociation of the FXIIIIA2B2 complex. Information in this regard would further contribute to the final elucidation of the FXIIIIA2B2 complex structure and its dynamics during assembly or dissociation.
How to cite this article: Gupta, S. et al. Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective. Sci. Rep. 6, 30105; doi: 10.1038/srep30105 (2016).
Lorand, L., Losowsky, M. S. & Miloszewski, K. J. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb. 5, 245–290 (1980).
Schwartz, M. L., Pizzo, S. V., Hill, R. L. & McKee, P. A. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation and cross-linking of fibrinogen and fibrin. J Biol Chem. 248, 1395–1407 (1973).
Muszbek, L., Ariens, R. A. & Ichinose, A. & Isth Ssc Subcommittee On Factor, X. Factor XIII: recommended terms and abbreviations. J Thromb Haemost. 5, 181–183 (2007).
Lorand, L. & Graham, R. M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 4, 140–156 (2003).
Klock, C. & Khosla, C. Regulation of the activities of the mammalian transglutaminase family of enzymes. Protein Sci. 21, 1781–1791 (2012).
Biswas, A., Ivaskevicius, V., Seitz, R., Thomas, A. & Oldenburg, J. An update of the mutation profile of Factor 13 A and B genes. Blood Rev. 25, 193–204 (2011).
Biswas, A., Ivaskevicius, V., Thomas, A. & Oldenburg, J. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie. 34, 160–166 (2014).
Biswas, A. et al. Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function. Ann Hematol. 93, 1665–1676 (2014).
Ivaskevicius, V. et al. A common F13A1 intron 1 variant IVS1 + 12(A) is associated with mild FXIII deficiency in Caucasian population. Ann Hematol. 92, 975–979 (2013).
Ivaskevicius, V. et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia. 16, 675–682 (2010).
Ivaskevicius, V. et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica. 95, 956–962 (2010).
Muszbek, L., Bereczky, Z., Bagoly, Z., Komaromi, I. & Katona, E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 91. 931–972 (2011).
Myneni, V. D., Hitomi, K. & Kaartinen, M. T. Factor XIII-A transglutaminase acts as a switch between preadipocyte proliferation and differentiation. Blood. 124, 1344–1353 (2014).
Malara, A. et al. Megakaryocyte-matrix interaction within bone marrow: new roles for fibronectin and factor XIII-A. Blood. 117, 2476–2483 (2011).
Gemmati, D. et al. Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? Thromb Haemost. 114, 123–132 (2015).
Wang, Z. et al. Pathogen entrapment by transglutaminase—a conserved early innate immune mechanism. PLoS Pathog. 6(29), e1000763 (2010).
Aeschlimann, D. & Thomazy, V. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res. 41, 1–27 (2000).
Raghu, H. et al. Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion. Blood. 125, 427–437 (2015).
Grundmann, U., Amann, E., Zettlmeissl, G. & Kupper, H. A. Characterization of cDNA coding for human factor XIIIa. Proc Natl Acad Sci. 83, 8024–8028 (1986).
Ichinose, A., Hendrickson, L. E., Fujikawa, K. & Davie, E. W. Amino acid sequence of the a subunit of human factor XIII. Biochemistry. 25, 6900–6906 (1986).
Ichinose, A., McMullen, B. A., Fujikawa, K. & Davie, E. W. Amino acid sequence of the b subunit of human factor XIII, a protein composed of ten repetitive segments. Biochemistry. 25, 4633–4638 (1986).
Yee, V. C. et al.Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci. 91, 7296–7300 (1994).
Yee, V. C., Pedersen, L. C., Bishop, P. D., Stenkamp, R. E. & Teller, D. C. Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII. Thromb Res. 78, 389–397 (1995).
Weiss, M. S., Metzner, H. J. & Hilgenfeld, R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett. 423, 291–296 (1998).
Fox, B. A. et al. Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by x-ray crystallography. J Biol Chem 274, 4917–4923 (1999).
Stieler, M. et al. Structure of active coagulation factor XIII triggered by calcium binding: basis for the design of next-generation anticoagulants. Angew Chem Int Ed Engl. 52, 11930–11934 (2013).
Carrell, N. A., Erickson, H. P. & McDonagh, J. Electron microscopy and hydrodynamic properties of factor XIII subunits. J Biol Chem. 264, 551–556 (1989).
Biswas, A., Thomas, A., Bevans, C. G., Ivaskevicius, V. & Oldenburg, J. In vitro secretion deficits are common among human coagulation factor XIII subunit B missense mutants: correlations with patient phenotypes and molecular models. Hum Mutat. 34, 1490–1500 (2013).
Souri, M., Kaetsu, H. & Ichinose, A. Sushi domains in the B subunit of factor XIII responsible for oligomer assembly. Biochemistry. 47, 8656–8664 (2008).
Katona, E. et al. Interaction of factor XIII subunits. Blood. 123, 1757–1763 (2014).
Souri, M., Osaki, T. & Ichinose, A. The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking. J Biol Chem. 290, 12027–12039 (2015).
Schroeder, V. Handrkova, H., Dodt, J. & Kohler, H. P. Free factor XIII activation peptide affects factor XIII function. Br J Haematol. 168, 757–759 (2015).
Leung-Toung, R. et al. 3-Substituted imidazo[1,2-d][1,2,4]-thiadiazoles: a novel class of factor XIIIa inhibitors. J Med Chem. 48, 2266–2269 (2005).
Lorand, J. B., Pilkington, T. R. & Lorand, L. Inhibitors of fibrin cross-linking: relevance for thrombolysis. Nature. 210, 1273–1274 (1966).
Lorand, L., Chou, C. H. & Simpson, I. Thiolester substrates for transamidating enzymes: studies on fibrinoligase. Proc Natl Acad Sci. 69, 2645–2648 (1972).
Finney, S., Seale, L., Sawyer, R. T. & Wallis, R. B. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J. 324 (Pt 3), 797–805 (1997).
Tymiak, A. A., Tuttle, J. G., Kimball, S. D., Wang, T. & Lee, V. G. A simple and rapid screen for inhibitors of factor XIIIa. J Antibiot (Tokyo). 46, 204–206 (1993).
Heil, A., Weber, J., Buchold, C., Pasternack, R. & Hils, M. Differences in the inhibition of coagulation factor XIII-A from animal species revealed by Michael Acceptor- and thioimidazol based blockers. Thromb Res. 131, e214–e222 (2013).
Komaromi, I., Bagoly, Z. & Muszbek, L. Factor XIII: novel structural and functional aspects. J Thromb Haemost. 9, 9–20 (2011).
Liu, S., Cerione, R. A. & Clardy, J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci. 99, 2743–2747 (2002).
Krieger, E., Koraimann, G. & Vriend, G. Increasing the precision of comparative models with YASARA NOVA—a self-parameterizing force field. Proteins. 47, 393–402 (2002).
Krieger, E. & Vriend, G. YASARA View - molecular graphics for all devices - from smartphones to workstations. Bioinformatics. 30, 2981–2982 (2014).
Choi, Y. & Deane, C. M. FREAD Revisited: Accurate loop structure prediction using a database search algorithm. Proteins, 78, 1431–1440 (2009).
Case, D. A. et al. The Amber biomolecular simulation programs. J Comput Chem. 26, 1668–1688 (2005).
Hooft, R. W., Vriend, G., Sander, C. & Abola, E. E. Errors in protein structures. Nature 381, 272 (1996).
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 25, 1605–1612 (2004).
Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J Mol Biol. 372, 774–797 (2007).
Baker, N. A., Sept, D., Joseph, S., Holst, M. J. & Mc Cammon, J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci. 98, 10037–10041 (2001).
Das, A. et al. Exploring the conformational transitions of biomolecular systems using a simple two-state anisotropic network model. PLoS Comput Biol. 10, e1003521 (2014).
Moore, B. L., Kelley, L. A., Barber, J., Murray, J. W. & MacDonald, J. T. High-quality protein backbone reconstruction from alpha carbons using Gaussian mixture models. J Comput Chem. 34, 1881–1889 (2013).
Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 5, 725–738 (2010).
Pierce, B., Tong, W. & Weng, Z. M-ZDOCK: a grid-based approach for Cn symmetric multimer docking. Bioinformatics. 21, 1472–1478 (2005).
Soares, D. C., Gerloff, D. L., Syme, N. R., Coulson, A. F., Parkinson, J. & Barlow, P. N. Large-scale modelling as a route to multiple surface comparisons of the CCP module family. Protein Eng Des Sel. 18, 379–388 (2005).
Dodt, J., Volkers, P. & Seitz, R. Factor XIIIa generation assay: a tool for studying factor XIII function in plasma. Anal Biochem. 439, 145–151 (2013).
Jang, T. H. et al. Crystal structure of transglutaminase 2 with GTP complex and amino acid sequence evidence of evolution of GTP binding site. PLoS One 9, e107005 (2014)
Stamnaes, J., Pinkas, D. M., Fleckenstein, B., Khosla, C. & Sollid, L. M. Redox regulation of transglutaminase 2 activity. J Biol Chem. 285, 25402–25409 (2010).
Lai, T. S., Slaughter, T. F., Peoples, K. A. & Greenberg, C. S. Site-directed mutagenesis of the calcium-binding site of blood coagulation factor XIIIa. J Biol Chem. 274, 24953–24958 (1999).
Handrkova, H., Schroeder, V. & Kohler, H. P. The activation peptide of coagulation factor XIII is vital for its expression and stability. J Thromb Haemost. 13, 1449–1458 (2015).
Simón, L. & Goodman, J. M. Enzyme catalysis by hydrogen bonds: the balance between transition state binding and substrate binding in oxyanion holes. J Org Chem. 75(6), 1831–1840 (2010).
Turner, B. T. Jr., Sabo, T. M., Wilding, D. & Maurer, M. C. Mapping of factor XIII solvent accessibility as a function of activation state using chemical modification methods. Biochemistry. 43, 9755–9765 (2004).
Sabo, T. M., Brasher, P. B. & Maurer, M. C. Perturbations in factor XIII resulting from activation and inhibition examined by solution based methods and detected by MALDI-TOF MS. Biochemistry. 46, 10089–10101 (2007).
Kristiansen, G. K. & Andersen, M. D. Reversible activation of cellular factor XIII by calcium. J Biol Chem. 286, 9833–9839 (2011).
Mary, A., Achyuthan, K. E. & Greenberg, C. S. b-chains prevent the proteolytic inactivation of the a-chains of plasma factor XIII. Biochim Biophys Acta. 8;966(3), 328–335 (1988).
Curtis, C. G. et al. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry. 13(18), 3774–3780 (1974).
Bagoly, Z., Haramura, G. & Muszbek, L. Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot. Thromb Haemost. 98, 359–367 (2007).
Robinson, B. R., Houng, A. K. & Reed, G. L. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. Circulation. 5;102(10), 1151–1157 (2000).
Hur, W. S. et al. Coagulation factor XIIIa is inactivated by plasmin. Blood. 126(20), 2329–2337 (2015).
Baker, S. B. & Worthley, L. I. The essentials of calcium, magnesium and phosphate metabolism: part I. Physiology. Crit Care Resusc. 4(4), 301–306 (2002).
Polgar, J., Hidasi, V. & Muszbek, L. Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). Biochem J. 267, 557–560 (1990).
The authors would like to acknowledge Prof. Dr. Hartmut Michel (Max Planck Institute for Biophysics, Frankfurt) for providing the infrastructure for performing gel filtration analysis. Mohammad Ahmar Jamil (IHT,Bonn) and Peter Volkars (PEI, Langen) for the heat map generation and biostatistical analysis. Dorothea Hausleithner (PEI, Langen) for help with the FXIII generation assay. Sophie Lyonga (IHT, Bonn) for technical help. The authors would like to acknowledge CSL Behring for funding research on Factor XIII.
The authors declare no competing financial interests.
Electronic supplementary material
About this article
Cite this article
Gupta, S., Biswas, A., Akhter, M. et al. Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective. Sci Rep 6, 30105 (2016). https://doi.org/10.1038/srep30105
This article is cited by
Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin
Journal of Thrombosis and Thrombolysis (2021)
Structure functional insights into calcium binding during the activation of coagulation factor XIII A
Scientific Reports (2019)
Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains
Journal of Thrombosis and Thrombolysis (2019)